A GLP-1 receptor agonist used in weight loss injections to regulate appetite and improve glycemic control.
Key difference
Single incretin pathway targeting satiety and glucose balance, with established clinical consistency.
A dual GIP/GLP-1 agonist designed for enhanced metabolic response and improved fat loss outcomes.
Key difference
Dual-pathway mechanism delivering stronger metabolic regulation compared to single agonists.
A triple agonist targeting GLP-1, GIP, and glucagon receptors for advanced metabolic modulation.
Key difference
Multi-pathway activation supports higher efficiency in fat loss and energy regulation.
Precision
Consistency
Scale